. 2006 Feb 6;34(3):840–852. doi: 10.1093/nar/gkj489

Table 1.

Standardized incidence ratios (SIRs) of cancer risk by site in population-based and clinic-based ascertainment of MMR defective cancers

Tumor site	All MSI-H SIR (60)	Population-based SIR (60)	Clinic-based SIR (60)	Incidence per 100 000 (60)	Clinic-based SIR (63)	Incidence per 100 000 (63)	Combined incidence per 100 000 (60,63)
Colon	6.1 (5.2–7.2)	4.3 (3.4–5.3)	9.6 (7.5–12.3)	5319	N/A^a
Gastric	4.6 (2.7–6.6)	3.3 (1.4–5.4)	7.1 (3.1–11.7)	614	4	1291	802
Uterus	4.1 (2.9–5.6)	3.4 (1.9–4.8)	5.4 (3.1–7.9)	2440	N/A^a	8049	4020
Kidney	2.6 (1.4–4.0)	1.8 (0.5–3.3)	4.1 (1.5–7.1)	438	3	759	528
Lung	0.3 (0.2–0.5)	0.2 (0.0–0.4)	0.6 (0.2–1.1)	351
Ovary	2.0 (1.0–3.2)	1.6 (0.5–3.1)	2.6 (0.8–5.1)	714	3.5	1974^b	1069^b
Breast	0.5 (0.3–0.7)	0.4 (0.2–0.6)	0.6 (0.3–1.0)	1250	<1
Hematopoietic	0.5 (0.2–0.8)	0.7 (0.2–1.1)	0.3 (0.0–0.7)	321	1
Pancreas	1.7 (0.7–2.8)	2.1 (0.8–3.8)	1.0 (0.0–2.7)	292	1
Prostate	0.3 (0.1–0.5)	0.3 (0.1–0.6)	0.3 (0.0–0.7)	292
Small bowel	7.6 (2.5–13.9)	9.7 (1.9–19.3)	3.6 (0.0–12.0)	175	25	759	338
Cervix	0.3 (0.1–0.5)	0.2 (0.0–0.4)	0.5 (0.0–0.9)	357	1	1063^b	556^b
Bladder	0.4 (0.1–0.9)	0.3 (0.0–0.7)	0.8 (0.0–1.8)	146	1	380	211
Hepatobiliary	2.4 (0.6–5.0)	0.9 (0.0–3.2)	5.3 (0.0–11.7)	117	5	532	232
Ureter	9.0 (2.0–18.3)	10.0 (0.0–22.9)	6.8 (0.0–21.8)	117	22	380	190
Brain	0.7 (0.0–1.7)	0.7 (0.0–1.9)	0.6 (0.0–2.1)	88	1
Head/neck	0.3 (0.0–0.6)	0.4 (0.0–0.9)	N/A	88	1
Melanoma	0.3 (0.0–0.4)	0.2 (0.0–0.6)	N/A	58

^aIn this study, these cancers were used to ascertain high-risk families, therefore an unbiased estimate of incidence cannot be estimated.

^bEstimated 50% of patients were female in this study.

Relative risk is presented with 95% confidence intervals in parentheses. Data are compiled from (60,63).